treatment
chronic
hepat
c
chc
continu
import
grow
challeng
respons
rate
fdaapprov
treatment
improv
past
decad
face
increas
number
difficulttotreat
patient
fail
prior
antivir
therapi
role
amantadin
treatment
chc
remain
unclear
studi
thu
far
produc
conflict
result
type
ii
error
could
exclud
review
summar
result
publish
literatur
review
exist
question
controversi
regard
use
amantadin
current
literatur
suggest
amantadin
ineffect
monotherapi
amantadin
increas
sustain
virolog
respons
certain
treatment
patient
use
combin
interferon
may
effect
adjunct
interferonbas
combin
therapi
patient
fail
relaps
prior
therapi
factor
small
sampl
size
patient
characterist
differ
treatment
protocol
includ
amantadin
prepar
durat
therapi
might
explain
conflict
observ
variou
studi
investig
need
defin
optim
dose
formul
amantadin
appropri
role
manag
chc
infect
hepat
c
viru
hcv
major
caus
chronic
liver
diseas
hepatocellular
carcinoma
lead
indic
liver
transplant
us
alon
approxim
million
peopl
infect
die
year
consequ
hcvrelat
liver
diseas
standard
care
treatment
chronic
hepat
c
chc
infect
evolv
stepwis
progress
past
year
interferonalpha
million
unit
mu
given
subcutan
inject
three
time
weekli
result
sustain
virolog
respons
svr
patient
wherea
combin
interferonalpharibavirin
achiev
overal
respons
rate
approach
two
form
newer
longeract
pegyl
interferonalpha
provid
increment
advantag
standard
interferon
combin
ribavirin
achiev
svr
depend
hcv
genotyp
despit
advanc
signific
number
patient
fail
respond
current
standard
antivir
regimen
especi
patient
unfavour
featur
genotyp
infect
high
viral
load
major
patient
us
chc
come
year
face
increas
proport
patient
andor
treatment
failur
antivir
agent
specif
target
key
enzym
hcv
viral
cycl
remain
investig
altern
agent
amantadin
may
repres
import
adjunct
treatment
option
especi
grow
patient
popul
fail
prior
antivir
therapi
first
report
demonstr
efficaci
amantadin
treatment
chc
publish
smith
colleagu
describ
group
patient
fail
interferonalpha
monotherapi
subsequ
clear
viru
retreat
amantadin
mg
twice
daili
month
sinc
initi
report
clinic
studi
provid
conflict
result
amantadin
use
alon
combin
interferonalpha
interferonalpha
ribavirin
studi
suggest
amantadin
littl
impact
svr
use
alon
produc
best
modest
improv
svr
combin
interferonalpha
interferonalpha
plu
ribavirin
review
investig
potenti
role
amanatidin
treatment
chc
base
result
publish
end
amantadin
water
solubl
tricycl
amin
use
clinic
prevent
influenza
viral
infect
known
antivir
effect
famili
rna
virus
togaviru
myxoviru
coronaviru
flaviviru
hepat
c
member
effect
mediat
inhibit
earli
step
influenza
viral
replic
interact
viral
membran
matrix
protein
function
ion
channel
requir
intern
viru
endocytosi
mechan
amantadin
antivir
agent
hepat
c
remain
uncertain
earli
studi
show
amantadin
reduc
hcv
rna
content
cultur
peripher
blood
mononuclear
cell
infect
patient
inhibit
hcv
protein
key
compon
ion
channel
format
despit
observ
vitro
biochem
assay
demonstr
amantadin
fail
inhibit
key
regulatori
enzym
step
viral
replic
includ
hcv
proteas
helicas
atpas
rnadepend
rna
polymeras
hcv
intern
ribosom
entri
site
translat
effect
amantadin
hcv
like
involv
immunemedi
process
amantadin
may
induc
product
interleukin
therefor
amantadin
may
best
use
adjunct
interferon
ribavirin
produc
addit
synergist
effect
addit
research
need
determin
amantadin
interact
host
viral
factor
modul
host
immun
system
basi
antivir
effect
literatur
search
perform
use
medlin
databas
identifi
public
decemb
medlin
keyword
search
conduct
use
mesh
term
hepat
c
viru
chronic
viral
hepat
amantadin
search
limit
englishlanguag
studi
adult
human
refer
list
retriev
public
examin
identifi
addit
citat
articl
abstract
review
determin
relev
manag
chc
infect
full
text
articl
obtain
analysi
clinic
studi
use
amantadin
treatment
chc
publish
sinc
clinic
trial
publish
use
amantadin
chc
form
basi
review
use
amantadin
patient
chronic
hepat
c
infect
amantadin
monotherapi
combin
interferon
thirteen
clinic
trial
studi
use
amantadin
firstlin
treatment
chc
infect
eightynin
patient
five
observ
trial
treat
amantadin
mg
daili
alon
month
although
biochem
respons
seen
patient
none
achiev
svr
six
random
trial
perform
evalu
interferonalpha
amantadin
combin
therapi
firstlin
therapi
caronia
et
al
demonstr
studi
patient
addit
amantadin
fixeddos
ifnalpha
mu
three
time
weekli
month
addit
improv
svr
without
amantadin
vs
amantadin
contrast
mangia
et
al
found
openlabel
prospect
studi
patient
addit
amantadin
fixeddos
ifnalpha
mu
three
time
weekli
month
result
statist
signific
increas
svr
p
recent
metaanalysi
individu
patient
data
six
trial
show
combin
interferonalpha
amantadin
appear
effect
result
pool
svr
p
metaanalysi
treatment
patient
treat
interferon
amantadin
receiv
interferon
monotherapi
baselin
characterist
favour
interferonamantadin
combin
therapi
monotherapi
includ
genotyp
p
high
viral
load
p
age
p
low
alt
level
p
absent
moder
fibrosi
p
logist
regress
analysi
show
interferonamantadin
combin
therapi
p
addit
age
genotyp
baselin
viraemia
independ
predictor
respons
difficult
treat
group
genotyp
high
viral
load
respons
rate
use
combin
therapi
vs
monotherapi
group
p
respons
similar
among
favour
genotyp
low
viral
load
import
conclus
perhap
fact
amantadin
improv
respons
rate
interferon
treatment
chc
patient
metaanalysi
howev
still
svr
current
interferon
ribavirin
combin
therapi
four
random
control
trial
evalu
role
interferon
combin
amantadin
induct
therapi
one
four
trial
show
addit
amantadin
interferon
induct
improv
svr
nakamura
et
al
studi
patient
addit
amantadin
mg
daili
increas
svr
patient
receiv
interferonbeta
mu
daili
week
follow
mu
three
time
weekli
week
vs
p
ns
zeuzem
et
al
studi
patient
addit
amantadin
mg
daili
increas
svr
patient
receiv
interferonalpha
mu
three
time
weekli
week
follow
mu
three
time
weekli
week
vs
p
ns
tabon
et
al
studi
patient
addit
amantadin
mg
daili
demonstr
statist
signific
increas
svr
patient
receiv
interferonalpha
mu
altern
day
month
follow
mu
altern
day
month
vs
p
ns
helb
et
al
perform
doubleblind
studi
patient
receiv
interferonalpha
mu
three
time
weekli
week
mu
three
time
weekli
remaind
month
cours
without
amantadin
mg
daili
addit
amantadin
result
statist
insignific
increas
svr
p
trial
suggest
amantadin
induct
therapi
ineffect
amantadin
combin
interferon
ribavirin
two
random
trial
evalu
role
tripl
therapi
interferonalpha
ribavirin
amantadin
manag
patient
ullerich
et
al
studi
patient
openlabel
prospect
studi
amantadin
mg
daili
ribavirin
mg
daili
given
patient
patient
random
receiv
either
low
induct
interferonalpha
mu
three
time
weekli
week
mu
three
time
weekli
week
high
induct
interferonalpha
mu
three
time
weekli
week
follow
mu
three
time
weekli
week
mu
three
time
weekli
week
mu
three
time
weekli
final
week
high
induct
interferon
regimen
result
larg
statist
signific
increas
svr
vs
p
ns
berg
et
al
perform
larg
random
doubleblind
trial
patient
given
induct
interferonalpha
mu
daili
week
follow
mu
daili
week
mu
three
time
weekli
week
addit
weightbas
ribavirin
mg
daili
patient
random
receiv
placebo
amantadin
mg
twice
daili
patient
receiv
amantadin
statist
signific
increas
svr
vs
p
ns
svr
higher
amantadin
group
vs
patient
genotyp
addit
multipl
logist
regress
analysi
show
amantadin
treatment
independ
factor
associ
svr
find
studi
metaanalysi
amantadineinterferon
combin
therapi
suggest
might
benefici
effect
amantadin
genotyp
patient
current
literatur
support
use
amantadin
monotherapi
first
line
treatment
chc
amantadin
may
limit
role
combin
interferonalpha
interferonalpha
plu
ribavirin
manag
patient
particularli
patient
genotyp
high
viral
load
eleven
trial
evalu
use
amantadin
treat
patient
chc
infect
previous
fail
interferon
monotherapi
three
small
observ
studi
involv
total
patient
demonstr
monotherapi
amantadin
mg
daili
fail
result
svr
patient
two
small
prospect
studi
evalu
role
amantadin
combin
interferonalpha
retreat
interferon
nonrespond
interferon
amantadin
teuber
et
al
perform
random
doubleblind
trial
patient
addit
amantadin
mg
interferonalpha
mu
three
time
weekli
week
mu
three
time
weekli
week
result
svr
p
ns
nonrandom
prospect
openlabel
trial
patient
given
interferonalpha
mu
daili
month
mu
three
time
weekli
month
without
amantadin
mg
daili
addit
amantadin
result
singl
case
svr
p
ns
first
random
prospect
openlabel
trial
khalili
et
al
demonstr
cohort
patient
treat
amantadin
mg
daili
mu
interferonalpha
tiw
inferior
interferon
ribavirin
mg
daili
patient
six
month
svr
vs
respect
p
ns
random
doubleblind
trial
younossi
colleagu
patient
retreat
week
either
two
regimen
interferonalpha
mu
three
time
weekli
ribavirin
mg
daili
ii
interferonalpha
mu
three
time
weekli
amantadin
mg
daili
none
patient
receiv
amantadin
achiev
svr
patient
receiv
combin
interferonribavirin
clear
viru
p
studi
demonstr
combin
interferon
amantadin
ineffect
initi
studi
berg
et
al
describ
consecut
interferon
nonrespond
given
induct
therapi
interferonalpha
mu
daili
week
follow
mu
altern
day
week
mu
three
time
weekli
week
mu
three
time
weekli
week
well
ribavirin
mg
daili
amantadin
mg
daili
none
patient
achiev
svr
contrast
three
studi
suggest
amantadin
tripl
therapi
might
benefici
pilot
nonrandom
prospect
openlabel
trial
patient
addit
amantadin
interferon
mu
altern
day
ribavirin
mg
daili
result
larg
statist
signific
increas
svr
vs
p
followup
random
openlabel
trial
patient
research
group
also
demonstr
addit
amantadin
result
statist
signific
increas
efficaci
vs
p
adinolfi
et
al
perform
largest
random
trial
address
question
studi
patient
random
three
group
fix
dose
interferonalpha
mu
three
time
weekli
oral
ribavirin
mg
daili
ii
induct
interferonalpha
mu
daili
week
mu
three
time
weekli
plu
oral
ribavirin
mg
daili
iii
induct
interferonalpha
ribavirin
plu
oral
amantadin
mg
daili
result
svr
respect
p
studi
demonstr
combin
induct
interferonalpha
ribavirin
amantadin
result
statist
signific
increas
svr
conflict
find
like
result
uniformli
small
sampl
size
import
differ
treatment
regimen
exampl
metaanalysi
patient
sampl
size
treatment
arm
need
detect
margin
increas
svr
addit
amantadin
studi
inadequ
power
detect
small
benefit
amantadin
studi
younossi
et
al
also
sever
shortcom
although
optim
durat
treatment
amantadin
interferon
remain
unknown
possibl
full
antivir
effect
combin
therapi
underestim
shortcours
treatment
week
studi
demonstr
minimum
week
interferon
necessari
achiev
sustain
viral
clearanc
patient
genotyp
amantadin
antivir
effect
may
mediat
part
uniqu
synergist
interact
interferon
ribavirin
therefor
may
underestim
trial
evalu
tripl
therapi
addit
effect
may
underpow
low
ribavirin
dose
use
studi
mg
daili
previou
studi
clearli
demonstr
ribavirin
exert
antivir
effect
dosedepend
manner
therefor
comparison
studi
use
higher
dose
made
contrast
brillanti
adinolfi
trial
evalu
amantadin
compon
tripl
therapi
full
cours
demonstr
impress
increas
svr
compar
standard
combin
interferonribavirin
regimen
trial
adinolfi
best
power
address
question
patient
addit
demonstr
induct
therapi
week
daili
interferon
may
increment
benefit
amantadin
may
import
role
adjunct
combin
interferonribavirin
therapi
interferon
nonrespond
although
prospect
random
trial
need
elucid
optim
dose
durat
identifi
predict
factor
success
current
literatur
strongli
suggest
amantadin
effect
monotherapi
combin
interferon
retreat
interferon
nonrespond
may
role
adjunct
standard
interferonalpha
ribavirin
therapi
treatment
interferonnonrespond
although
current
data
conflict
three
small
observ
studi
evalu
efficaci
amantadin
treat
patient
fail
respond
combin
interferonribavirin
interferon
monotherapi
interferonribavirin
retreat
dimartino
et
al
treat
consecut
patient
fail
either
interferon
interferonribavirin
amantadin
mg
daili
month
although
result
decreas
alt
patient
none
achiev
svr
p
ns
thuluvath
et
al
studi
consecut
interferon
ribavirin
nonrespond
retreat
patient
tripl
combin
therapi
interferonalpha
mu
three
time
weekli
ribavirin
mg
daili
amantadin
mg
daili
month
result
svr
suggest
retreat
combin
therapi
amantadin
may
result
viral
clearanc
small
number
patient
younossi
et
al
treat
consecut
interferon
monotherapi
combin
interferonribavirin
nonrespond
tripl
combin
therapi
interferonalpha
mu
three
time
weekli
ribavirin
mg
daili
amantadin
mg
daili
week
achiev
svr
two
patient
amantadin
may
result
viral
clearanc
small
group
patient
fail
interferon
combin
interferonribavirin
result
trial
limit
small
sampl
size
therefor
may
inadequ
support
definit
conclus
effect
amantadin
patient
fail
standard
combin
interferonribavirin
four
trial
three
observ
studi
one
openlabel
random
trial
evalu
role
amantadin
patient
respond
relaps
prior
therapi
interferon
andor
interferonribavirin
tabon
et
al
treat
interferon
relaps
amantadin
monotherapi
amantadin
mg
daili
month
none
patient
achiev
svr
carlsson
et
al
treat
nonrespond
relaps
interferonribavirin
combin
tripl
therapi
interferon
mu
three
time
weekli
ribavirin
mg
daili
amantadin
mg
daili
week
find
achiev
svr
respect
suggest
amantadin
effect
nonrespond
may
result
svr
small
number
relaps
combin
therapi
weeginth
et
al
random
patient
respond
relaps
previou
interferon
interferonribavirin
therapi
either
two
tripl
therapi
regimen
patient
receiv
initi
week
induct
therapi
highdos
interferonalpha
mu
three
time
weekli
ribavirin
amantadin
follow
addit
week
ribavirin
amantadin
without
addit
interferonalpha
mu
three
time
weekli
none
patient
receiv
week
induct
interferon
achiev
viral
clearanc
contrast
high
percentag
patient
complet
week
tripl
therapi
induct
standard
interferonalpha
achiev
svr
p
studi
demonstr
retreat
tripl
therapi
may
highli
effect
small
subset
relaps
previou
interferon
interferonribavirin
therapi
noni
genotyp
demonstr
virolog
respons
within
week
initi
therapi
zilli
et
al
perform
observ
studi
patient
nonrespond
either
interferon
interferon
ribavirin
relaps
interferon
experienc
breakthrough
interferon
interferonribavirin
patient
treat
tripl
therapi
interferonalpha
mu
three
time
weekli
ribavirin
mg
daili
amantadin
mg
daili
month
interferon
mu
three
time
weekli
monotherapi
addit
month
although
previou
nonrespond
achiev
svr
regimen
signific
number
patient
initi
respond
relaps
interferon
experienc
breakthrough
interferon
interferonribavirin
achiev
svr
respect
result
suggest
retreat
tripl
therapi
may
highli
effect
select
group
patient
initi
respons
interferon
interferonribavirin
may
littl
valu
initi
nonrespond
role
amantadin
treatment
relaps
interferon
interferonribavirin
remain
unclear
current
literatur
remain
inadequ
properli
assess
role
popul
howev
trial
suggest
amantadin
monotherapi
doubl
therapi
interferonamantadin
ribavirinamantadin
appear
effect
clear
viru
importantli
data
addit
highlight
amantadin
tripl
therapi
interferonribavirinamantadin
may
achiev
significantli
higher
rate
sustain
viral
clearanc
relaps
initi
nonrespond
although
studi
grossli
underpow
demonstr
statist
signific
differ
current
data
show
amantadin
may
promis
adjunct
target
popul
studi
larger
random
trial
studi
examin
role
amantadin
special
patient
popul
summar
elderli
remain
understudi
popul
treatment
chc
infect
drug
trial
explicitli
exclud
patient
age
therefor
littl
data
avail
guid
standard
care
patient
pauciti
data
reflect
origin
nih
consensu
develop
statement
manag
hepat
c
support
routin
use
interferonbas
therapi
patient
age
year
incomplet
although
formal
recommend
made
recent
consensu
statement
clear
controversi
remain
safeti
efficaci
interferonbas
therapi
popul
balanc
risk
benefit
newer
regimen
use
antivir
agent
favour
side
effect
profil
need
provid
altern
option
patient
interferon
ribavirin
may
contraind
amantadin
typic
welltoler
side
effect
nausea
lightheaded
decreas
concentr
decreas
appetit
anxieti
rare
caus
seriou
reaction
agit
hallucin
seizur
torr
et
al
treat
consecut
elderli
patient
chc
age
mean
age
amantadin
monotherapi
although
treatment
found
safe
side
effect
amantadin
fail
achiev
either
sustain
biochem
virolog
respons
summari
amantadin
appear
safe
welltoler
medic
elderli
effect
chc
treatment
hcv
patient
coinfect
human
immunodefici
viru
hiv
continu
import
challeng
highli
activ
antiretrovir
therapi
result
markedli
improv
life
span
patient
hiv
infect
liver
diseas
becom
increasingli
common
caus
morbid
mortal
popul
therapi
current
approv
unit
state
food
drug
administr
hivhcv
coinfect
recent
nih
consensu
develop
confer
statement
recommend
treatment
consid
casebi
case
basi
particularli
stabl
hiv
infect
wellcompens
liver
diseas
sever
small
trial
suggest
combin
interferonalpharibavirin
safe
welltoler
patient
may
achiev
rate
sustain
viral
clearanc
similar
hcv
monoinfect
patient
pegyl
interferon
popul
like
superior
standard
combin
interferonalpha
ribavirin
sax
et
al
perform
pilot
studi
nine
patient
hiv
coinfect
antiretrovir
therapi
treat
interferonalpha
without
amantadin
neither
treatment
regimen
result
svr
suggest
addit
amantadin
interferon
littl
effect
patient
popul
hepat
c
infect
recur
nearli
patient
follow
liver
transplant
hcvrelat
cirrhosi
may
contribut
acceler
rate
fibrosi
patient
routin
chemoprevent
treatment
current
recommend
set
absenc
data
although
data
limit
small
studi
demonstr
combin
interferonalpha
ribavirin
may
effect
patient
poorli
toler
requir
drug
reduct
withdraw
pilot
data
present
septemb
american
colleg
gastroenterolog
confer
suggest
pegyl
interferonribavirin
achiev
high
rate
sustain
viral
clearanc
patient
abl
complet
month
therapi
treatment
withdraw
occur
nearli
patient
clearli
newer
regimen
better
toler
agent
need
andreon
et
al
studi
nine
consecut
patient
recurr
posttransplant
hepat
c
infect
administ
tripl
therapi
interferonalpha
mu
three
time
weekli
ribavirin
mg
daili
amantadin
mg
daili
month
unfortun
treatment
poorli
toler
two
requir
discontinu
within
first
month
one
patient
abl
complet
month
therapi
treatment
tripl
therapi
significantli
decreas
alt
level
baselin
patient
complet
treatment
achiev
svr
histolog
improv
liver
biopsi
seen
two
patient
suggest
tripl
therapi
amantadin
posttranspl
patient
may
result
viral
clearanc
abl
toler
therapi
month
one
studi
evalu
impact
amantadin
healthrel
qualiti
life
use
interferon
nonrespond
analysi
show
substanti
improv
depress
score
profil
mood
state
scale
subscal
fatigu
p
vigour
p
among
patient
receiv
interferonalpha
amantadin
compar
receiv
interferonalpha
alon
like
amantadin
reduc
sideeffect
ifn
previou
studi
demonstr
interferonbas
regimen
may
significantli
improv
qualiti
life
score
along
subscal
survey
instrument
treatment
particularli
patient
achiev
svr
although
mechan
action
remain
unclear
amantadin
may
improv
qualiti
life
amelior
symptom
associ
chc
infect
andor
sideeffect
interferon
therapi
review
publish
data
suggest
amatadin
may
minor
role
treatment
chc
although
mani
issu
remain
unresolv
optim
formul
dosag
amantadin
exampl
poorli
studi
although
amantadin
hydrochlorid
primari
drug
form
studi
research
trial
sever
investig
use
amantadin
sulphat
combin
regimen
possibl
choic
formul
may
affect
treatment
outcom
metaanalysi
interferonamantadin
combin
therapi
treatment
patient
signific
differ
respons
rate
among
patient
receiv
amantadin
hydrochlorid
instead
amantadin
sulphat
p
typic
dose
use
studi
rang
mg
daili
although
unknown
higher
dose
would
result
higher
efficaci
major
drawback
exist
data
includ
small
sampl
size
wide
diverg
select
patient
treatment
protocol
sever
studi
stratifi
patient
accord
genotyp
major
predictor
respons
interferonbas
therapi
may
explain
differ
result
observ
differ
countri
genotyp
distribut
larg
region
natur
addit
sever
studi
use
nonstandard
dose
interferon
without
induct
make
comparison
pool
data
difficult
howev
studi
demonstr
amantadin
effect
monotherapi
poorli
effect
use
interferon
alon
amantadin
may
use
safe
welltoler
adjunct
combin
interferonribavirin
therapi
treatment
patient
fail
interferon
interferonribavirin
chc
infect
tabl
major
advantag
amantadin
favour
safeti
toler
profil
low
cost
although
weak
antivir
agent
indirect
effect
viral
replic
multipl
observ
studi
random
trial
suggest
combin
regimen
amantadin
may
significantli
increas
rate
sustain
viral
clearanc
nonrespond
responderrelaps
breakthrough
respond
interferon
interferonribavirin
absenc
avail
therapi
target
hcv
viral
replic
cycl
amantadin
may
repres
suitabl
option
properli
select
patient
larger
random
trial
need
defin
role
amantadin
manag
hepat
c
infect
particularli
combin
newer
pegyl
interferonbas
regimen
special
understudi
popul
elderli
patient
hivcoinfect
recurr
hcv
follow
liver
transplant
